RU2722784C2 - Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf - Google Patents

Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf Download PDF

Info

Publication number
RU2722784C2
RU2722784C2 RU2016129287A RU2016129287A RU2722784C2 RU 2722784 C2 RU2722784 C2 RU 2722784C2 RU 2016129287 A RU2016129287 A RU 2016129287A RU 2016129287 A RU2016129287 A RU 2016129287A RU 2722784 C2 RU2722784 C2 RU 2722784C2
Authority
RU
Russia
Prior art keywords
cas
pharmaceutically acceptable
bvd
cancer
agent
Prior art date
Application number
RU2016129287A
Other languages
English (en)
Russian (ru)
Other versions
RU2016129287A (ru
Inventor
Саурабх САХА
Дин УЭЛШ
Гари ДЕКРЕСЕНЗО
Джеффри Джеймс РОЙКС
Original Assignee
Байомед Вэлли Дискавериз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байомед Вэлли Дискавериз, Инк. filed Critical Байомед Вэлли Дискавериз, Инк.
Publication of RU2016129287A publication Critical patent/RU2016129287A/ru
Application granted granted Critical
Publication of RU2722784C2 publication Critical patent/RU2722784C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2016129287A 2013-12-20 2014-12-19 Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf RU2722784C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361919347P 2013-12-20 2013-12-20
US61/919,347 2013-12-20
PCT/US2014/071715 WO2015095819A2 (en) 2013-12-20 2014-12-19 Cancer treatment using combinations of erk and raf inhibitors

Publications (2)

Publication Number Publication Date
RU2016129287A RU2016129287A (ru) 2018-01-23
RU2722784C2 true RU2722784C2 (ru) 2020-06-03

Family

ID=53403899

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016129287A RU2722784C2 (ru) 2013-12-20 2014-12-19 Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf

Country Status (11)

Country Link
US (1) US10668055B2 (enExample)
EP (3) EP3082800B1 (enExample)
JP (1) JP6678585B2 (enExample)
CN (1) CN106211755B (enExample)
AU (1) AU2014368906B2 (enExample)
BR (1) BR112016014481B1 (enExample)
CA (4) CA2934669C (enExample)
ES (2) ES3063344T3 (enExample)
MX (2) MX394252B (enExample)
RU (1) RU2722784C2 (enExample)
WO (1) WO2015095819A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017095826A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Combination therapy for treatment of melanoma
KR20180118141A (ko) * 2016-02-05 2018-10-30 에볼 사이언스 엘엘씨 암 치료를 위한 조합
US10752589B2 (en) * 2016-03-14 2020-08-25 Sphaera Pharma Pvt. Ltd. Trigonelline based compounds
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
WO2018213302A1 (en) * 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
CA3066350A1 (en) * 2017-06-06 2018-12-13 The Johns Hopkins University Induction of synthetic lethality with epigenetic therapy
WO2019032561A1 (en) 2017-08-07 2019-02-14 Evol Science LLC COMBINATIONS FOR THE TREATMENT OF CANCER
EP3694518A1 (en) * 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
SG11202003886TA (en) * 2017-11-01 2020-05-28 Nat Univ Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
AU2018368639B2 (en) * 2017-11-20 2025-02-27 Tolremo Therapeutics Ag Diagnostic method
WO2019103984A1 (en) * 2017-11-22 2019-05-31 Memorial Sloan Kettering Cancer Center Compositions including fatp1, fatp3, fatp4, fatp5, and/or fatp6 inhibitors and uses thereof
WO2019195959A1 (en) * 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
CA3211167A1 (en) * 2021-02-19 2022-08-25 Samuel C. BLACKMAN Combination of raf inhibitor and mek inhibitor
CN113018269B (zh) * 2021-03-14 2022-06-03 华中科技大学同济医学院附属协和医院 复合颗粒物、其制备方法及其应用
KR20240044419A (ko) * 2021-06-24 2024-04-04 에라스카, 아이엔씨. Erk1/2 및 egfr 억제제 조합 요법
CN118510505A (zh) * 2021-10-28 2024-08-16 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
JP2024542019A (ja) * 2021-11-02 2024-11-13 ベラステム・インコーポレーテッド 異常な細胞成長を処置する方法
CN116251085B (zh) * 2021-12-10 2026-08-07 南方医科大学 Kobe2602或其药物可接受盐在制备抗埃博拉病毒药物中的应用
CN115400122B (zh) * 2022-04-29 2023-04-18 佛山病原微生物研究院 一种tak-632在制备用于抗腺病毒感染的药物中的用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2025010293A2 (en) * 2023-07-03 2025-01-09 Immuneering Corporation Mek immune oncology inhibitor pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354939B2 (en) * 2004-05-14 2008-04-08 Vertex Pharmaceuticals Incorporated Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
US20130296318A1 (en) * 2009-08-28 2013-11-07 Shenlin Huang Compounds and compositions as protein kinase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507926A (ja) 1993-03-19 1996-08-27 シーケノム・インコーポレーテツド エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
JP2008545670A (ja) 2005-05-27 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 疾患を処置するためのジアリールウレア類を含む組合せ治療
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR068046A1 (es) * 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
TWI419974B (zh) 2008-10-27 2013-12-21 Qiagen Gaithersburg Inc 於自動平台上之快速結果雜交捕捉法
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
WO2012068562A2 (en) * 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354939B2 (en) * 2004-05-14 2008-04-08 Vertex Pharmaceuticals Incorporated Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
US20130296318A1 (en) * 2009-08-28 2013-11-07 Shenlin Huang Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIN F. et al., Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor, Bioorg Med Chem. 2013 Sep 15;21(18): C.5694-706. MORRIS E.J. et al., Discovery of a novel ERK inhibitor with activity in models *
JIN F. et al., Exploration of N-(2-aminoethyl)piperidine-4-carboxamide as a potential scaffold for development of VEGFR-2, ERK-2 and Abl-1 multikinase inhibitor, Bioorg Med Chem. 2013 Sep 15;21(18): C.5694-706. MORRIS E.J. et al., Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEKinhibitors, Cancer Discov. 2013 Jul;3(7):742-50. *

Also Published As

Publication number Publication date
EP4043017B1 (en) 2026-01-28
WO2015095819A2 (en) 2015-06-25
CA3300955A1 (en) 2026-03-02
EP4732908A3 (en) 2026-07-22
CA3168002C (en) 2024-10-22
EP4043017A1 (en) 2022-08-17
WO2015095819A3 (en) 2015-08-13
MX384721B (es) 2025-03-14
AU2014368906B2 (en) 2020-04-30
BR112016014481B1 (pt) 2022-11-08
CN106211755A (zh) 2016-12-07
EP3082800A2 (en) 2016-10-26
US10668055B2 (en) 2020-06-02
RU2016129287A (ru) 2018-01-23
CA2934669A1 (en) 2015-06-25
CA2934669C (en) 2022-10-04
MX2021008610A (es) 2022-07-27
US20160310476A1 (en) 2016-10-27
JP2017502017A (ja) 2017-01-19
JP6678585B2 (ja) 2020-04-22
EP3082800A4 (en) 2017-07-05
CA3168002A1 (en) 2015-06-25
EP4732908A2 (en) 2026-04-29
ES3063344T3 (en) 2026-04-16
AU2014368906A1 (en) 2016-07-21
BR112016014481A2 (pt) 2018-02-20
CN106211755B (zh) 2021-06-22
CA3240745A1 (en) 2015-06-25
ES2909910T3 (es) 2022-05-10
CA3240745C (en) 2026-06-02
MX2016008201A (es) 2017-04-27
MX394252B (es) 2025-03-21
EP3082800B1 (en) 2022-02-02

Similar Documents

Publication Publication Date Title
AU2023204587B2 (en) Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers
CN110799245B (zh) 用于治疗具有非典型braf突变的癌症的组合物和方法
AU2020202555B2 (en) Novel fusion molecules and uses thereof
AU2014368927B2 (en) Cancer treatments using combinations of CDK and ERK inhibitors
CA2934669C (en) Cancer treatment using combinations of erk and raf inhibitors
AU2014368912B2 (en) Cancer treatments using combinations of type 2 MEK and ERK inhibitors
US20210324478A1 (en) Compositions and methods for identification assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators
RU2812706C2 (ru) Композиции и способы для лечения злокачественной опухоли с атипичными мутациями braf
HK40022785B (en) Compositions and methods for treating cancer with atypical braf mutations
HK40022785A (en) Compositions and methods for treating cancer with atypical braf mutations
HK40075625B (en) Cancer treatment using combinations of erk and raf inhibitors
HK40006110A (en) Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
HK40075625A (en) Cancer treatment using combinations of erk and raf inhibitors
HK40108769A (en) Cancer treatments using combinations of type 2 mek and erk inhibitors